title: Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers.
abstract: Biodegradable microparticles made of poly(lactide-co-glycolide) (PLG) were used for protracted and pulsed-release of the incorporated ricin toxoid (RT) vaccine to reduce the multiple immunization doses and the time required to induce complete protection against lethal aerosol-borne ricin challenge. The release rate of RT encapsulated in PLG microparticles was controlled by polymer selection and varying the preparation procedures, which allowed us to control microparticle size and the distribution of the vaccine in the polymeric matrix. PLG-microparticles in which RT vaccine was distributed heterogeneously in small pockets stimulated a rapid antibody response which was independent of the polymeric composition of the carriers. PLG-microparticles in which RT vaccine was distributed homogeneously throughout the polymeric matrix induced a slower antibody response, which depended on the polymeric composition of the carriers. Administration of RT in homogeneous microparticles made from 50/50 PLG or 100% polylactide stimulated two distinct anti-ricin IgG peaks, while RT in heterogeneous microparticles stimulated identical IgG peaks. An early (3 weeks) and long-lasting (1 year or longer) anti-ricin antibody response was evoked by a single administration of encapsulated RT vaccine when prepared by the above-mentioned conditions. In contrast, three administrations of the aqueous RT were required to stimulate similar antibody response. Reduction of immunization time from 6 to 4 weeks was achieved with RT encapsulated in small homogeneous microparticles but not with homogeneous large microparticles. These results demonstrated the usefulness of biodegradable microparticles to improve the efficacy of immunization with RT vaccine and probably many other vaccines as well.
authors.affiliation: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011, USA.
authors.forename: C
authors.initials: C
authors.lastname: Yan
authors.forename: W L
authors.initials: WL
authors.lastname: Rill
authors.forename: R
authors.initials: R
authors.lastname: Malli
authors.forename: J
authors.initials: J
authors.lastname: Hewetson
authors.forename: R
authors.initials: R
authors.lastname: Tammariello
authors.forename: M
authors.initials: M
authors.lastname: Kende
mesh_terms: D000818:Animals; D000917:Antibody Formation; D004337:Drug Carriers; D005260:Female; D007114:Immunization; D007074:Immunoglobulin G / Q000096:biosynthesis; D019344:Lactic Acid; D051379:Mice; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage*; D012276:Ricin / Q000008:administration & dosage / Q000276:immunology*; D014121:Toxoids / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D004337:Drug Carriers; D007074:Immunoglobulin G; D011108:Polymers; D014121:Toxoids; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D012276:Ricin